Home LiteratureArticle Details
PMID: 18363999 Published · ppublish English Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review

Polarized immune responses differentially regulate cancer development.

Immunological reviews ·Vol. 222 ·2008-04-00 ·Pages 145-54

Johansson M, Denardo DG, Coussens LM

Abstract

Tumor-associated immune responses assert varied responses toward developing neoplasms that can either act to eradicate malignant cells via engagement of potent cytotoxic programs or alternatively enhance tumor growth through release of multifunctional pro-tumor mediators. Seemingly paradoxical, these disparate activities reflect a continuum of polarization (or activation) states possible for distinct leukocyte subsets that demonstrate tissue, organ, and tumor selectivity. Herein, we review clinical and experimental studies investigating cellular and molecular mechanisms utilized by neoplastic tissues to alternatively polarize immune responses that favor either pro- or anti-tumor immunity.

MeSH Terms
Animals Cell Lineage/immunology Cell Transformation, Neoplastic/immunology Humans Immunity, Cellular Immunity, Innate Inflammation/immunology Mice Neoplasms/blood supply,immunology,pathology,therapy Neovascularization, Pathologic Rats Receptors, Fc/immunology Suppressor Factors, Immunologic/immunology T-Lymphocyte Subsets/immunology T-Lymphocytes, Regulatory/immunology Toll-Like Receptors/immunology
Chemicals
Receptors, Fc Suppressor Factors, Immunologic Toll-Like Receptors
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Johansson Magnus
Department of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.
Denardo David G
Coussens Lisa M
References (93)
93 references, click to expand
  1. Epigenetic control in the immune response.
    Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R41-6 PMID: 15809272
  2. Adoptive-cell-transfer therapy for the treatment of patients with cancer.
    Nat Rev Cancer. 2003 Sep;3(9):666-75 PMID: 12951585
  3. Immune cells as anti-cancer therapeutic targets and tools.
    J Cell Biochem. 2007 Jul 1;101(4):918-26 PMID: 17265430
  4. Cancer despite immunosurveillance: immunoselection and immunosubversion.
    Nat Rev Immunol. 2006 Oct;6(10):715-27 PMID: 16977338
  5. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells.
    Int J Cancer. 2005 Nov 20;117(4):574-86 PMID: 15912532
  6. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.
    Nature. 2006 May 11;441(7090):235-8 PMID: 16648838
  7. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.
    Cancer Cell. 2005 May;7(5):411-23 PMID: 15894262
  8. IL-23 promotes tumour incidence and growth.
    Nature. 2006 Jul 27;442(7101):461-5 PMID: 16688182
  9. Development of TLR9 agonists for cancer therapy.
    J Clin Invest. 2007 May;117(5):1184-94 PMID: 17476348
  10. Friends or foes - bipolar effects of the tumour stroma in cancer.
    Nat Rev Cancer. 2004 Nov;4(11):839-49 PMID: 15516957
  11. Role of circulating immune complexes in prognostic evaluation and management of genitourinary cancer patients.
    Indian J Cancer. 1997 Sep;34(3):111-20 PMID: 9491672
  12. Derangement of immune responses by myeloid suppressor cells.
    Cancer Immunol Immunother. 2004 Feb;53(2):64-72 PMID: 14593498
  13. Tumor stroma and regulation of cancer development.
    Annu Rev Pathol. 2006;1:119-50 PMID: 18039110
  14. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
    J Immunol. 1999 Nov 15;163(10):5211-8 PMID: 10553041
  15. The immune system. Second of two parts.
    N Engl J Med. 2000 Jul 13;343(2):108-17 PMID: 10891520
  16. Cancer immunoediting: from immunosurveillance to tumor escape.
    Nat Immunol. 2002 Nov;3(11):991-8 PMID: 12407406
  17. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
    Science. 2006 Sep 29;313(5795):1960-4 PMID: 17008531
  18. A universal role for MyD88 in TLR/IL-1R-mediated signaling.
    Trends Biochem Sci. 2002 Sep;27(9):474-82 PMID: 12217523
  19. A critical function for type I interferons in cancer immunoediting.
    Nat Immunol. 2005 Jul;6(7):722-9 PMID: 15951814
  20. Immunological enhancement of primary tumor development and its prevention.
    Semin Cancer Biol. 2000 Oct;10(5):351-7 PMID: 11100883
  21. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    J Immunol. 1998 Dec 15;161(12):6977-84 PMID: 9862733
  22. Toll-like receptors: critical proteins linking innate and acquired immunity.
    Nat Immunol. 2001 Aug;2(8):675-80 PMID: 11477402
  23. Antibodies, Fc receptors and cancer.
    Curr Opin Immunol. 2007 Apr;19(2):239-45 PMID: 17291742
  24. Prognostic significance of circulating immune complexes in malignant tumours of head and neck.
    J Indian Med Assoc. 1995 Jan;93(1):3-7 PMID: 7759908
  25. Immune complex-dependent remodeling of the airway vasculature in response to a chronic bacterial infection.
    J Immunol. 2005 Nov 15;175(10):6319-26 PMID: 16272283
  26. Toll-like receptors, endogenous ligands, and systemic autoimmune disease.
    Immunol Rev. 2005 Apr;204:27-42 PMID: 15790348
  27. Th17: an effector CD4 T cell lineage with regulatory T cell ties.
    Immunity. 2006 Jun;24(6):677-688 PMID: 16782025
  28. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms.
    Arthritis Rheum. 2006 Aug;54(8):2356-67 PMID: 16868991
  29. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model.
    J Immunol. 2002 Jul 1;169(1):375-83 PMID: 12077267
  30. Developmental commitment to the Th2 lineage by extinction of IL-12 signaling.
    Immunity. 1995 Jun;2(6):665-75 PMID: 7796298
  31. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer.
    Cell. 2006 Feb 24;124(4):823-35 PMID: 16497591
  32. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88.
    J Immunol. 2005 Jun 15;174(12):7912-9 PMID: 15944297
  33. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion.
    Cancer Immunol Immunother. 2000 Jan;48(10):541-9 PMID: 10630306
  34. Toll-like receptors in systemic autoimmune disease.
    Nat Rev Immunol. 2006 Nov;6(11):823-35 PMID: 17063184
  35. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy.
    Nat Rev Cancer. 2007 Nov;7(11):880-7 PMID: 17957190
  36. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
    Cancer Immunol Immunother. 2005 Aug;54(8):721-8 PMID: 16010587
  37. Hyaluronan stimulates tumor cell migration by modulating the fibrin fiber architecture.
    J Cell Sci. 1999 Jul;112 ( Pt 13):2241-51 PMID: 10362554
  38. NF-kappaB: linking inflammation and immunity to cancer development and progression.
    Nat Rev Immunol. 2005 Oct;5(10):749-59 PMID: 16175180
  39. Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder.
    Cancer Immunol Immunother. 2006 Jun;55(6):734-43 PMID: 16283306
  40. Immunosuppressive networks in the tumour environment and their therapeutic relevance.
    Nat Rev Cancer. 2005 Apr;5(4):263-74 PMID: 15776005
  41. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma.
    Cancer. 1997 Jun 15;79(12):2320-8 PMID: 9191519
  42. B cell immunobiology in disease: evolving concepts from the clinic.
    Annu Rev Immunol. 2006;24:467-96 PMID: 16551256
  43. Novel antibody-based therapy for acute lymphoblastic leukaemia.
    Best Pract Res Clin Haematol. 2006;19(4):701-13 PMID: 16997178
  44. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.
    Nature. 2003 Feb 13;421(6924):744-8 PMID: 12610626
  45. Phenotypic and functional features of human Th17 cells.
    J Exp Med. 2007 Aug 6;204(8):1849-61 PMID: 17635957
  46. B-cell targeting in rheumatoid arthritis and other autoimmune diseases.
    Nat Rev Immunol. 2006 May;6(5):394-403 PMID: 16622478
  47. The immunobiology of cancer immunosurveillance and immunoediting.
    Immunity. 2004 Aug;21(2):137-48 PMID: 15308095
  48. Induction of interferon-gamma production in Th1 CD4+ T cells: evidence for two distinct pathways for promoter activation.
    Eur J Immunol. 1999 Feb;29(2):548-55 PMID: 10064070
  49. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells.
    J Immunol. 2001 May 1;166(9):5398-406 PMID: 11313376
  50. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
    Nat Med. 2004 Sep;10(9):942-9 PMID: 15322536
  51. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.
    Int Immunol. 2001 Apr;13(4):459-63 PMID: 11282985
  52. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes.
    J Immunother. 2004 Jul-Aug;27(4):273-81 PMID: 15235388
  53. Divergent immunoglobulin g subclass activity through selective Fc receptor binding.
    Science. 2005 Dec 2;310(5753):1510-2 PMID: 16322460
  54. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
    Cancer Res. 1999 Jul 1;59(13):3128-33 PMID: 10397255
  55. Pathogen recognition and innate immunity.
    Cell. 2006 Feb 24;124(4):783-801 PMID: 16497588
  56. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
    Nat Med. 2007 Sep;13(9):1050-9 PMID: 17704786
  57. Inflammation and cancer: back to Virchow?
    Lancet. 2001 Feb 17;357(9255):539-45 PMID: 11229684
  58. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis.
    Cancer Cell. 2004 Oct;6(4):409-21 PMID: 15488763
  59. Inflammation and cancer.
    Nature. 2002 Dec 19-26;420(6917):860-7 PMID: 12490959
  60. Smoldering and polarized inflammation in the initiation and promotion of malignant disease.
    Cancer Cell. 2005 Mar;7(3):211-7 PMID: 15766659
  61. Clinical utility and monitoring of breast cancer by circulating immune complexes.
    Indian J Pathol Microbiol. 1992 Oct;35(4):298-307 PMID: 1344219
  62. Effects of PSK on T and dendritic cells differentiation in gastric or colorectal cancer patients.
    Anticancer Res. 2005 Jan-Feb;25(1B):443-9 PMID: 15816609
  63. Humoral immunity, inflammation and cancer.
    Curr Opin Immunol. 2007 Apr;19(2):209-16 PMID: 17276050
  64. Biology and biochemistry of proteinases in tumor invasion.
    Physiol Rev. 1993 Jan;73(1):161-95 PMID: 8419965
  65. Paradoxical roles of the immune system during cancer development.
    Nat Rev Cancer. 2006 Jan;6(1):24-37 PMID: 16397525
  66. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.
    Cancer Res. 2005 Apr 15;65(8):3044-8 PMID: 15833831
  67. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88.
    Science. 2007 Jul 6;317(5834):124-7 PMID: 17615359
  68. T-cell regulation by CD28 and CTLA-4.
    Nat Rev Immunol. 2001 Dec;1(3):220-8 PMID: 11905831
  69. Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer.
    J Immunol. 2001 Sep 1;167(5):2972-8 PMID: 11509647
  70. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.
    Science. 2006 Aug 4;313(5787):670-3 PMID: 16888140
  71. Lipid mediator class switching during acute inflammation: signals in resolution.
    Nat Immunol. 2001 Jul;2(7):612-9 PMID: 11429545
  72. IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family.
    J Allergy Clin Immunol. 1999 Jan;103(1 Pt 1):11-24 PMID: 9893178
  73. Fc receptors and their interaction with complement in autoimmunity.
    Immunol Lett. 2005 Aug 15;100(1):56-67 PMID: 16125792
  74. Toll-like receptor signalling.
    Nat Rev Immunol. 2004 Jul;4(7):499-511 PMID: 15229469
  75. The hallmarks of cancer.
    Cell. 2000 Jan 7;100(1):57-70 PMID: 10647931
  76. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process.
    Cancer Res. 2002 Dec 1;62(23):7042-9 PMID: 12460925
  77. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells.
    Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15137-42 PMID: 11752460
  78. Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies.
    Neoplasia. 1999 Nov;1(5):453-60 PMID: 10933061
  79. The perfect mix: recent progress in adjuvant research.
    Nat Rev Microbiol. 2007 Jul;5(7):505-17 PMID: 17558426
  80. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide.
    Blood. 2002 Sep 1;100(5):1728-33 PMID: 12176894
  81. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice.
    Am J Pathol. 1996 Dec;149(6):1899-917 PMID: 8952526
  82. Putting tumours in context.
    Nat Rev Cancer. 2001 Oct;1(1):46-54 PMID: 11900251
  83. Pulmonary T cells and eosinophils: coconspirators or independent triggers of allergic respiratory pathology?
    J Allergy Clin Immunol. 2001 Jun;107(6):945-57 PMID: 11398070
  84. CD4+ Tregs and immune control.
    J Clin Invest. 2004 Nov;114(9):1209-17 PMID: 15520849
  85. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies.
    Ann Rheum Dis. 2001 May;60(5):433-41 PMID: 11302861
  86. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.
    Science. 2007 Jul 6;317(5834):121-4 PMID: 17615358
  87. Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer.
    Adv Cancer Res. 2002;84:231-76 PMID: 11883529
  88. Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment.
    Immunity. 2000 Jan;12(1):27-37 PMID: 10661403
  89. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo.
    Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):419-24 PMID: 15623559
  90. Fc receptors and their role in immune regulation and autoimmunity.
    J Clin Immunol. 2005 Jan;25(1):1-18 PMID: 15742153
  91. Clinical significance of defective dendritic cell differentiation in cancer.
    Clin Cancer Res. 2000 May;6(5):1755-66 PMID: 10815894
  92. Translating innate immunity into immunological memory: implications for vaccine development.
    Cell. 2006 Feb 24;124(4):849-63 PMID: 16497593
  93. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
    Int J Urol. 2004 Dec;11(12):1070-7 PMID: 15663677
Article Info
Journal
Immunological reviews
Abbr.
Immunol Rev
ISSN
1600-065X
DOI
10.1111/j.1600-065X.2008.00600.x
Published
2008-04-00
Pages
145-54
Language
English
Region
England
NLM ID
7702118
PMCID
PMC2494984
Subset
IM
Grants
NCI NIH HHS · R01 CA098075 · United States
NCI NIH HHS · R01 CA094168 · United States
NCI NIH HHS · R01 CA094168-05 · United States
NCI NIH HHS · CA72006 · United States
NCI NIH HHS · P01 CA072006 · United States
NCI NIH HHS · CA098075 · United States
NCI NIH HHS · R01 CA098075-05 · United States
NCI NIH HHS · P01 CA072006-06A29002 · United States
NCRR NIH HHS · U54 RR020843-045942 · United States
NCI NIH HHS · CA94168 · United States
NCRR NIH HHS · U54 RR020843 · United States
External Links
PubMed source DOI: 10.1111/j.1600-065X.2008.00600.x PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2